Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.

Asenbaum S, Brücke T, Pirker W, Podreka I, Angelberger P, Wenger S, Wöber C, Müller C, Deecke L.

J Nucl Med. 1997 Jan;38(1):1-6.

2.

Iometopane: (123)I beta-CIT, dopascan injection, GPI 200, RTI 55.

[No authors listed]

Drugs R D. 2003;4(5):320-2. Review.

PMID:
12952503
3.

Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders.

Kugaya A, Fujita M, Innis RB.

Ann Nucl Med. 2000 Feb;14(1):1-9. Review.

PMID:
10770574
4.

IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism.

Tissingh G, Booij J, Winogrodzka A, van Royen EA, Wolters EC.

J Neural Transm Suppl. 1997;50:31-7. Review.

PMID:
9120422
5.

How useful is (123I) beta-CIT SPECT in the diagnosis of Parkinson's disease?

Bhidayasiri R.

Rev Neurol Dis. 2006 Winter;3(1):19-22. Review.

PMID:
16596082
6.
7.

SPECT and PET imaging of the dopaminergic system in Parkinson's disease.

Brücke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, Podreka I.

J Neurol. 2000 Sep;247 Suppl 4:IV/2-7. Review.

PMID:
11199811
8.

N-(3-Fluoropropyl)-2β-carbomethoxy-3β-(4-[123I]iodophenyl)nortropane.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2004 Dec 16 [updated 2011 Feb 1].

9.
10.

Neuroinflammation in the living brain of Parkinson's disease.

Ouchi Y, Yagi S, Yokokura M, Sakamoto M.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S200-4. doi: 10.1016/S1353-8020(09)70814-4. Review.

PMID:
20082990
11.

[Is functional imaging useful in the clinical evaluation of Parkinson's disease?].

Remy P.

Rev Neurol (Paris). 2003 May;159(5 Pt 2):3S57-61. Review. French.

PMID:
12773889
12.

3-β-(4-Iodophenyl)tropane-2-β-carboxylic acid 2-[18F]fluoroethyl ester .

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Aug 11 [updated 2008 Sep 17].

13.

Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease.

Marek K, Jennings D, Seibyl J.

Adv Neurol. 2003;91:183-91. Review. No abstract available.

PMID:
12442677
14.

The role of radiotracer imaging in Parkinson disease.

Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A, Fahn S, Guttman M, Gwinn-Hardy K, McFarland H, Innis R, Katz RG, Kieburtz K, Kish SJ, Lange N, Langston JW, Marek K, Morin L, Moy C, Murphy D, Oertel WH, Oliver G, Palesch Y, Powers W, Seibyl J, Sethi KD, Shults CW, Sheehy P, Stoessl AJ, Holloway R.

Neurology. 2005 Jan 25;64(2):208-15. Review.

PMID:
15668415
15.

Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.

Au WL, Adams JR, Troiano AR, Stoessl AJ.

Brain Res Mol Brain Res. 2005 Mar 24;134(1):24-33. Epub 2004 Nov 2. Review.

PMID:
15790527

Supplemental Content

Support Center